Independent Investors Inc. Invests $1,033,000 in Shire PLC (SHPG)
Independent Investors Inc. bought a new position in shares of Shire PLC (NASDAQ:SHPG) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,612 shares of the biopharmaceutical company’s stock, valued at approximately $1,033,000.
Other large investors have also recently modified their holdings of the company. Sequoia Financial Advisors LLC purchased a new stake in shares of Shire PLC during the second quarter worth $258,000. CAM Group Holding A S raised its stake in shares of Shire PLC by 1.5% in the second quarter. CAM Group Holding A S now owns 106,494 shares of the biopharmaceutical company’s stock worth $19,603,000 after buying an additional 1,570 shares during the period. Henderson Group PLC purchased a new stake in shares of Shire PLC during the second quarter worth $4,032,000. Roberts Glore & Co. Inc. IL purchased a new stake in shares of Shire PLC during the second quarter worth $282,000. Finally, Concert Wealth Management Inc. purchased a new stake in shares of Shire PLC during the second quarter worth $389,000. 24.30% of the stock is owned by institutional investors and hedge funds.
Shares of Shire PLC (NASDAQ:SHPG) traded up 2.64% during mid-day trading on Tuesday, hitting $190.70. The stock had a trading volume of 3,164,596 shares. The firm has a 50 day moving average price of $194.54 and a 200 day moving average price of $188.15. Shire PLC has a 52-week low of $147.60 and a 52-week high of $231.32. The firm has a market cap of $56.80 billion, a PE ratio of 39.63 and a beta of 1.16.
Shire PLC (NASDAQ:SHPG) last released its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.03 by $0.35. The firm earned $2.43 million during the quarter, compared to analyst estimates of $2.28 billion. Shire PLC had a return on equity of 17.70% and a net margin of 13.19%. Shire PLC’s revenue was up 55.9% compared to the same quarter last year. During the same period last year, the business posted $2.63 earnings per share. Equities analysts predict that Shire PLC will post $12.92 EPS for the current year.
The business also recently announced a dividend, which was paid on Friday, October 7th. Investors of record on Friday, September 9th were issued a $0.139 dividend. The ex-dividend date was Wednesday, September 7th. Shire PLC’s dividend payout ratio (DPR) is presently 15.63%.
A number of equities research analysts have weighed in on the company. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Shire PLC in a research report on Monday. Goldman Sachs Group Inc. reissued a “buy” rating on shares of Shire PLC in a research report on Sunday. Shore Capital reissued a “buy” rating on shares of Shire PLC in a research report on Saturday, October 8th. Leerink Swann reissued a “buy” rating on shares of Shire PLC in a research report on Saturday, October 1st. Finally, Piper Jaffray Cos. set a $201.00 price target on Shire PLC and gave the stock a “hold” rating in a research report on Saturday, October 1st. Five equities research analysts have rated the stock with a hold rating and twenty-two have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $228.15.
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.